{"links": [{"source": 0, "target": "t6992", "value": "None"}, {"source": 0, "target": "t6995", "value": "None"}, {"source": 0, "target": "t6994", "value": "None"}, {"source": 0, "target": "t6986", "value": "None"}, {"source": 0, "target": "t6988", "value": "None"}, {"source": "t6992", "target": "t6996", "value": "None"}, {"source": "t6992", "target": "t6993", "value": "None"}, {"source": "t6986", "target": "t6987", "value": "None"}, {"source": "t6986", "target": "t6991", "value": "None"}, {"source": "t6988", "target": "t6989", "value": "None"}, {"source": "t6989", "target": "t6990", "value": "None"}, {"source": "t6990", "target": "d162", "value": "None"}], "nodes": [{"category": "disease", "id": 0, "name": "Liver_conditions_general_and_other", "x": "250", "y": "350", "fixed": "true", "draggable": "true", "value": {"name": "Liver_conditions_general_and_other"}}, {"category": "treatment", "id": "t6992", "name": "non alcoholic fatty liver disease", "draggable": "true", "value": {"name": "non alcoholic fatty liver disease", "type": "treatment related", "time": "", "intention": "", "description": "title:non-alcoholic fatty liver disease", "drug": {}}}, {"category": "treatment", "id": "t6995", "name": "advanced liver fibrosis (adults)", "draggable": "true", "value": {"name": "advanced liver fibrosis (adults)", "type": "treatment related", "time": "", "intention": "", "description": "title:advanced liver fibrosis (adults)", "drug": {}}}, {"category": "treatment", "id": "t6994", "name": "advanced liver fibrosis (child)", "draggable": "true", "value": {"name": "advanced liver fibrosis (child)", "type": "treatment related", "time": "", "intention": "", "description": "title:advanced liver fibrosis (child)", "drug": {}}}, {"category": "treatment", "id": "t6986", "name": "person over 16 with suspected cirrhosis", "draggable": "true", "value": {"name": "person over 16 with suspected cirrhosis", "type": "disease name and patient related", "time": "", "intention": "", "description": "title:person over 16 with suspected cirrhosis", "drug": {}}}, {"category": "treatment", "id": "t6988", "name": "testing, diagnosis and referral", "draggable": "true", "value": {"name": "testing, diagnosis and referral", "type": "treatment related", "time": "", "intention": "", "description": "title:testing, diagnosis and referralhead:Testing, diagnosis and referralsubhead:Testing and diagnosisDiscuss with the person the accuracy, limitations and risks of the different tests for diagnosing cirrhosis.Offer transient elastography to diagnose cirrhosis for: people with hepatitis C virus infection men who drink over 50 units of alcohol per week and women who drink over 35 units of alcohol per week and have done so for several months people diagnosed with alcohol-related liver disease.Offer either transient elastography or acoustic radiation force impulse imaging (whichever is available) to diagnose cirrhosis for people with NAFLD and advanced liver fibrosis (as diagnosed by a score of 10.51 or above using the ELF test). See what NICE says on testing and diagnosis of advanced liver fibrosis in children and young people and testing, diagnosis and referral of advanced liver fibrosis in adults.Consider liver biopsy to diagnose cirrhosis in people for whom transient elastography is not suitable.For recommendations on diagnosing cirrhosis in people with hepatitis B virus infection, see assessment of liver disease in people with chronic hepatitis.Do not offer tests to diagnose cirrhosis for people who are obese (BMI of 30 kg/m2 or higher) or have type 2 diabetes, unless they have NAFLD and advanced liver fibrosis (as diagnosed by a score of 10.51 or above using the ELF test). See what NICE says on testing and diagnosis of advanced liver fibrosis in children and young people and testing, diagnosis and referral of advanced liver fibrosis in adults.Ensure that healthcare professionals who perform or interpret non-invasive tests are trained to do so.Do not use routine laboratory liver blood tests to rule out cirrhosis. subhead:ReferralRefer people diagnosed with cirrhosis to a specialist in hepatology.subhead:RetestingOffer retesting for cirrhosis every 2 years for: people diagnosed with alcohol-related liver disease people with hepatitis C virus infection who have not shown a sustained virological response to antiviral therapy people with NAFLD and advanced liver fibrosis.For recommendations on reassessing liver disease in hepatitis B virus infection, see assessment of liver disease in people with chronic hepatitis.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.3Non-invasive testing for cirrhosis (developmental)SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG50", "drug": {}}}, {"category": "treatment", "id": "t6996", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t6993", "name": "diagnosis and management", "draggable": "true", "value": {"name": "diagnosis and management", "type": "treatment related", "time": "", "intention": "", "description": "title:diagnosis and management", "drug": {}}}, {"category": "treatment", "id": "t6987", "name": "risk factors", "draggable": "true", "value": {"name": "risk factors", "type": "treatment related", "time": "", "intention": "", "description": "title:risk factorshead:Risk factorsBe aware that there is an increased risk of cirrhosis in people who: have hepatitis B virus infection have hepatitis C virus infection misuse alcohol are obese (BMI of 30 kg/m2 or higher)  have type 2 diabetes.Also see NICE s recommendations on treating primary biliary cholangitis.See what NICE says on non-alcoholic fatty liver disease, alcohol-use disorders, hepatitis, type 2 diabetes in adults and obesity.SourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG50", "drug": {}}}, {"category": "treatment", "id": "t6991", "name": "patient experience", "draggable": "true", "value": {"name": "patient experience", "type": "treatment related", "time": "", "intention": "", "description": "title:patient experience", "drug": {}}}, {"category": "treatment", "id": "t6989", "name": "monitoring", "draggable": "true", "value": {"name": "monitoring", "type": "treatment related", "time": "", "intention": "", "description": "title:monitoringhead:Monitoringsubhead:Risk of complications Refer people who have, or are at high risk of, complications of cirrhosis to a specialist hepatology centre.Calculate the MELD score every 6 months for people with compensated cirrhosis.Consider using a MELD score of 12 or more as an indicator that the person is at high risk of complications of cirrhosis.subhead:Hepatocellular carcinomaOffer ultrasound (with or without measurement of serum alpha-fetoprotein) every 6 months as surveillance for HCC for people with cirrhosis who do not have hepatitis B virus infection.For people with hepatitis B virus infection and cirrhosis see what NICE says on surveillance for hepatocellular carcinoma in adults.Do not offer surveillance for HCC for people who are receiving end of life care.subhead:Oesophageal varicesAfter a diagnosis of cirrhosis, offer upper gastrointestinal endoscopy to detect oesophageal varices.For people in whom no oesophageal varices have been detected, offer surveillance using upper gastrointestinal endoscopy every 3 years.subhead:Focal liver lesionsThe following recommendation is an extract from SonoVue (sulphur hexafluoride microbubbles) \u2013 contrast agent for contrast-enhanced ultrasound imaging of the liver.Contrast-enhanced ultrasound with SonoVue is recommended for characterising focal liver lesions in adults whose cirrhosis is being monitored: if contrast-enhanced MRI is not clinically appropriate, is not accessible or is not acceptable to the person, and when unenhanced ultrasound scan is inconclusive.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.4Surveillance for hepatocellular carcinomaSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG50DG5", "drug": {}}}, {"category": "treatment", "id": "t6990", "name": "managing complications", "draggable": "true", "value": {"name": "managing complications", "type": "treatment related", "time": "", "intention": "ciprofloxacin\nhas been used for treatment of bone and joint infections caused by susceptible gram-positive bacteria, including staphylococcus aureus\u2020,296 326 370 474 535 s. epidermidis\u2020,326 474 535 other coagulase-negative staphylococci\u2020,326 370 or enterococcus faecalis\u2020.370 other anti-infectives generally preferred for these gram-positive infections,522 538 but ciprofloxacin may be a useful alternative for treatment of infections caused by susceptible oxacillin-resistant (methicillin-resistant) staphylococci.522 538\nhas been used for treatment of meningitis and other cns infections\u2020 caused by susceptible gram-negative bacteria (e.g., ps. aeruginosa, salmonella) either alone or in conjunction with other drugs (e.g., aminoglycoside, ceftriaxone or cefotaxime).63 360 707 762 763 764 765 818\ntreatment of respiratory tract infections (including bronchiectasis,333 479 596 bronchitis,205 297 301 333 335 345 346 347 356 435 466 479 lung abscess,474 596 pneumonia)205 326 333 346 347 356 357 435 466 479 491 596 caused by susceptible e. cloacae,1 333 474 579 e. coli,1 333 345 355 491 579 haemophilus influenzae,1 297 301 324 333 346 351 380 427 491 596 579 h. parainfluenzae,1 297 474 579 k. pneumoniae,1 297 301 333 345 351 380 579 p. mirabilis,1 380 579 ps. aeruginosa,1 300 301 324 333 346 359 380 427 433 579 or s. pneumoniae;1 324 326 333 345 346 355 356 357 425 427 491 also has been used for respiratory tract infections caused by susceptible e. aerogenes\u2020,474 k. oxytoca\u2020,474 or s. aureus\u2020.333 345 380 491\nnot a drug of first choice for pneumonia caused by s. pneumoniae;1 579 778 generally should not be used for empiric treatment of community-acquired pneumonia (cap) when s. pneumoniae is likely or suspected.5 178 296 356 427 479 522 621 idsa and ats state that other fluoroquinolones with enhanced activity against s. pneumoniae (gemifloxacin, levofloxacin, moxifloxacin) are drugs of choice for empiric treatment of cap in outpatients at risk for infections caused by drug-resistant s. pneumoniae (drsp) and also are drugs of choice for empiric treatment of cap in inpatients.31\nprobably should not be used for treatment of aspiration pneumonia since these infections generally involve anaerobic bacteria.293 296 621\ntreatment of complicated or uncomplicated utis in adults caused by susceptible gram-negative bacteria, including citrobacter koseri (formerly c. diversus),1 579 778 c. freundii,1 339 340 341 375 380 474 579 778 e. cloacae,1 327 332 380 579 778 e. coli,1 297 326 327 329 332 336 338 339 340 351 352 353 375 380 504 579 778 856 k. pneumoniae,1 297 327 329 336 338 340 341 353 375 504 579 778 856 m. morganii,1 340 341 579 778 p. mirabilis,1 327 332 336 340 352 353 504 579 778 856 providencia rettgeri,1 474 579 778 ps. aeruginosa,1 297 300 326 327 336 338 339 340 341 351 353 359 375 379 380 538 579 778 856 or s. marcescens;1 340 341 353 380 504 579 778 also has been used for utis caused by e. aerogenes\u2020,474 klebsiella oxytoca\u2020,474 or p. stuartii\u2020.326 474\nbased on results of in vitro susceptibility testing, ciprofloxacin may be considered for use in combination antimycobacterial regimens used for treatment of infections caused by m. chelonae\u2020, m. haemophilum\u2020, or m. terrae\u2020.671 because of considerations related to resistance, not recommended for treatment of m. marinum infections.671\nhas been used for temporary elimination of oxacillin-resistant (methicillin-resistant) s. aureus colonization\u2020 in patients with serious diseases at risk for infection.410 479 consider that management of oxacillin-resistant s. aureus colonization is controversial, permanent eradication of nasal carriage of staphylococci following topical or systemic anti-infectives is unlikely, ciprofloxacin resistance has been reported in some oxacillin-resistant s. aureus,122 144 362 410 479 548 549 and there is some evidence that ciprofloxacin may be an independent risk factor for colonization with oxacillin-resistant s. aureus in hiv-infected patients.727\nhas been used for treatment of some rickettsial infections\u2020,393 538 568 625 including mediterranean spotted fever caused by rickettsia conorii\u2020.393\nchildren 2\u201312 years of age: a single dose of 20 mg/kg (up to 750 mg) has been used for treatment of cholera caused by v. cholerae 01 or 0139.758\nconventional tablets or oral suspension: 500 mg twice daily in conjunction with oral rifampin (600 mg once daily).771 772 alternatively, 500 mg 2 or 3 times daily for 6\u201312 weeks or 750 mg 3 times daily for 6\u20138 weeks has been used for brucellosis or acute brucella arthritis-diskitis.624 monotherapy or treatment regimens <4\u20136 weeks not recommended.683 772\n1 g given as a single dose or in 2 divided doses 12 hours apart has been used for treatment of cholera caused by v. cholerae 01 or 0139.664 757\nextended-release tablets: dosage adjustments not needed when 500-mg extended-release tablet used for treatment of uncomplicated utis (acute cystitis) in adults with renal impairment.856 decreased dosage recommended when used for treatment of complicated utis or acute uncomplicated pyelonephritis in adults with clcr \u226430 ml/minute.856 (see table 2.) do not use 1-g extended-release tablets in adults who have clcr \u226430 ml/minute or are undergoing hemodialysis or peritoneal dialysis.856\nadvise patients that antibacterials (including ciprofloxacin) should only be used to treat bacterial infections and not used to treat viral infections (e.g., the common cold).1 579 778 856\n855. wendte jm, ponnusamy d, reiber d et al. in vitro efficacy of antibiotics commonly used to treat human plague against intracellular yersinia pestis. antimicrob agents chemother. 2011; 55:3752-7. [pubmed 21628541]", "description": "title:managing complicationshead:Managing complicationsOffer endoscopic variceal band ligation for the primary prevention of bleeding for people with cirrhosis who have medium to large oesophageal varices.Offer prophylactic intravenous antibiotics for people with cirrhosis who have upper gastrointestinal bleeding.Review intravenous antibiotic prescriptions in line with NICE s recommendations on prescribing intravenous antimicrobials.Consider a transjugular intrahepatic portosystemic shunt for people with cirrhosis who have refractory ascites.Offer prophylactic oral ciprofloxacin or norfloxacinAt the time of publication (June 2016), neither ciprofloxacin nor norfloxacin have a UK marketing authorisation for this indication. The prescriber should follow relevant professional guidance, taking full responsibility for the decision. Informed consent should be obtained and documented. See GMC Prescribing guidance: Prescribing unlicensed medicines for further information. for people with cirrhosis and ascites with an ascitic protein level of 15 g/litre or less, until the ascites has resolved.See what NICE says on acute upper gastrointestinal bleeding and medicines optimisation.subhead:Rifaximin for recurrent overt hepatic encephalopathyThe following recommendation is from NICE technology appraisal guidance on rifaximin for preventing episodes of overt hepatic encephalopathy.Rifaximin is recommended, within its marketing authorisation, as an option for reducing the recurrence of episodes of overt hepatic encephalopathy in people aged 18 years or older.NICE has written information for the public explaining its guidance on rifaximin.subhead:Catheter drainage system for refractory and recurrent ascitesNICE has published interventional procedures guidance that subcutaneous implantation of a battery-powered catheter drainage system for managing refractory and recurrent ascites should be used only in the context of a formal research protocol.Quality standardsThe following quality statement is relevant to this part of the interactive flowchart.5Prophylactic intravenous antibiotics for upper gastrointestinal bleedingSourcesThe NICE guidance that was used to create this part of the interactive flowchart. NG50TA337", "drug": {}}}, {"category": "drug", "id": "d162", "name": "ciprofloxacin", "draggable": "true", "value": {"name": "ciprofloxacin", "time": "None", "period": "None", "dosage": "None"}}]}